2 ms·
This is really not surprising. Media coverage of 23andMe all the way back to its founding has said that it was offering SNP testing at-cost to build a big datab
by gwern 10y ago
This is really not surprising. Media coverage of 23andMe all the way back to its founding has said that it was offering SNP testing at-cost to build a big database which can be used for all sorts of things (although they were probably too optimistic about the usefulness of it). The real scandal is how 23andMe has published appallingly little research based on it. When I signed up with 23andMe, I was totally fine with them selling my genetic data; because I expected them to be participating in research. Instead, what we get is occasional cutesy stuff, occasional contribution of a cohort to other researchers, and a few papers a year on not particularly interesting topics like coffee consumption (some hits, naturally, since everything is heritable, but not an important topic). Contrast this to the UK Biobank which has been - with a fraction of the 23andMe sample size - releasing blockbuster paper after blockbuster paper over the past year alone!
- biomcgary 10y agoI think it may just be taking time for scientists to start working with their pipeline, which is somewhat cumbersome simply due to their privacy controls. I predict we will start seeing more studies soon. See my other comment on this thread for details about one of those studies.
- gwern 10y agoThat seems highly unlikely. 23andMe has been in operation since 2006. They hit UK Biobank sample size sometime around 2010. The Biobank researchers have been managing to pump out paper after paper (check out Bioxiv!) over the past half-year even though as far as I can tell, their genetics pipeline only started yielding data back around October 2015. How long are we supposed to wait on 23andMe before concluding that they just aren't making very good use of their data from the perspective of the public interest and have focused on commercialization?